Q3 2025 · 13F-HR
Euclidean Capital LLCholdings as filed
Filed 2025-11-14 · accession 0001012975-25-000761
$238.0M
Reported value
11
Positions
2025-09-30
Period end
The Brief · Euclidean Capital LLC · Q3 2025
AI · grounded in 13F
Euclidean Capital LLC established a new position in VEU valued at $184M. The fund also initiated new stakes in INDA for $19.2M and ORIC for $11.9M. Additional new positions include FHTX, ALEC, and PMVP.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 922042775 | VEU | VANGUARD INTL EQUITY INDEX F | $184.0M | 77.3% | 2,578,184 | Common | SOLE |
| 46429B598 | INDA | ISHARES TR | $19.2M | 8.08% | 369,600 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $11.9M | 4.99% | 989,410 | Common | SOLE |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $7.7M | 3.23% | 1,573,761 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $3.9M | 1.63% | 1,307,858 | Common | SOLE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $3.7M | 1.55% | 2,627,643 | Common | SOLE |
| 78462F103 | SPY | SPDR S&P 500 ETF TR | $2.7M | 1.15% | 4,104 | Common | SOLE |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $2.1M | 0.89% | 82,234 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $1.6M | 0.69% | 1,015,705 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $1.1M | 0.47% | 87,696 | Common | SOLE |
| 86889P117 | SRZNW | SURROZEN INC | $3,417 | 0.00% | 170,833 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.